Breakthrough invasive fungal diseases in acute myeloid leukemia patients receiving mould active triazole primary prophylaxis after intensive chemotherapy: An Italian consensus agreement on definitions and management

Corrado Girmenia, Alessandro Busca, Anna Candoni, Simone Cesaro, Mario Luppi, Anna Maria Nosari, Livio Pagano, Giuseppe Rossi, Adriano Venditti, Franco Aversa

Research output: Contribution to journalArticlepeer-review

Abstract

In the attempt to establish definitions and provide shared approaches to breakthrough invasive fungal diseases (br-IFD) in acute myeloid leukemia (AML) patients submitted to intensive chemotherapy and receiving triazoles as mould active primary antifungal prophylaxis (MA-PAP), literature on br-IFD in AML patients receiving triazoles MA-PAP was reviewed and a Consensus Development Conference Project was convened. The following four candidate key-questions were generated and formed the set of questions of the present document: "definition of br-IFD," "diagnostic strategy during MA-PAP to detect br-IFD," "possible causes of MA-PAP failure," "management of br-IFD."

Original languageEnglish
Pages (from-to)S127-S137
JournalMed. Mycol.
Volume57
Issue numberSupplement_2
DOIs
Publication statusPublished - Apr 1 2019

Keywords

  • Antifungal Agents/administration & dosage
  • Chemoprevention/methods
  • Disease Management
  • Humans
  • Invasive Fungal Infections/diagnosis
  • Italy/epidemiology
  • Leukemia, Myeloid, Acute/complications
  • Triazoles/administration & dosage

Fingerprint Dive into the research topics of 'Breakthrough invasive fungal diseases in acute myeloid leukemia patients receiving mould active triazole primary prophylaxis after intensive chemotherapy: An Italian consensus agreement on definitions and management'. Together they form a unique fingerprint.

Cite this